PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
Thyroid Cancer|Thyroid Cancer, Follicular|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Hurthle Cell Tumor|Poorly Differentiated Thyroid Gland Carcinoma|Hurthle Cell Thyroid Neoplasia
DRUG: Trametinib|DRUG: Dabrafenib|DRUG: PDR001
Overall response rate, The primary endpoint is to determine the overall response rate (ORR=CR+PR) as documented by RECIST v1.1 criteria within each cohort., 1 year
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.